01.06.25 -- A Fragmented Outsourcing Landscape: The Difficulties Of Working With Multiple Siloed Partners

Plan early and align research, development, and commercial priorities to ensure a seamless transition from clinical development to scalable, cost-efficient commercialization.

By working with a single supplier that can handle the entire manufacturing value chain, companies can reduce risk, improve flexibility, and accelerate their time to market.

Explore how platform processes advance gene therapies, the impact of strong partnerships on patient access, and the future shaped by these collaborations.

To stay ahead in the competitive landscape of mRNA development, adopt a comprehensive QC strategy today and begin conducting meaningful tests to ensure the quality of your test articles.

Explore the necessary components of a smooth tech transfer for LNP-based drugs, including the variables that impact LNP formulation and the outsourcing strategies needed to avoid common pitfalls.

Unlock the potential of AAV manufacturing by leveraging data-driven insights and the advanced Pro10™ platform to optimize processes, enhance productivity, and drive innovation in cell and gene therapy.

The integrity of your master cell bank (MCB) is paramount key in the production of advanced therapies. Selecting a provider with specialized expertise is crucial.

Explore specificities and challenges, leveraging automation for scalability with the Cocoon^® Platform, and building a vein-to-vein network to achieve ‘just-in-time’ delivery of therapies.